Device Trial Radar · NCT07655479
Rapid Impella Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
115
Planned (sponsor's estimate)
Start
Apr 23, 2026
Primary completion
Oct 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- University Hospital of CologneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Johnson & Johnson
- First posted
- Jun 17, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 77 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to evaluate whether a structured and time-optimized escalation strategy from a transfemoral microaxial flow-pump (Impella CP™) to the Impella 5.5™ microaxial flow-pump is associated with improved clinical outcomes and fewer adverse events in patients with cardiogenic shock due to acute myocardial infarction
Conditions
- Cardiogenic Shock Post Myocardial Infarction
Interventions
Escalation to more capable microaxial flow-pump (Impella 5.5)Device
Rapid escalation from Impella CP to Impella 5.5 within 24 hours post revascularization
Primary outcomes
What the sponsor says the trial is designed to measure.
- Vasoactive Hemodynamic Score (VHS) < 5Time frame: 48 hours post revascularization
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University Hospital Cologne
Cologne, Germany · Recruiting
University Hospital Düsseldorf
Düsseldorf, North Rhine-Westphalia, Germany · Recruiting
University Hospital Schleswig-Holstein, Campus Kiel
Kiel, Schleswig-Holstein, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.